Dr. Landgren on Investigational Cellular Therapies in Multiple Myeloma

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses investigational cellular therapies in multiple myeloma.

Multi-targeted CAR T-cell therapies may have efficacy in treating patients with multiple myeloma, says Landgren. Moreover, having multiple targets may eliminate the possibility of myeloma cells avoiding therapy through antigen downregulation.

CAR-expressing natural killer (NK) cells are also in development, says Landgren. While they have not shown reportable efficacy in multiple myeloma, they have shown promising results in lymphoma.

Additionally, CAR-expressing NK cells could provide an off-the-shelf option as opposed to traditional autologous CAR T cells that have to be manufactured for each individual patient, concludes Landgren.